• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

成人 AML 患者接受强度较低治疗的遗传风险分类：2024 年 ELN 建议。

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

机构信息

Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Blood. 2024 Nov 21;144(21):2169-2173. doi: 10.1182/blood.2024025409.

DOI:
10.1182/blood.2024025409
PMID:39133932
Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

摘要

欧洲白血病网络（ELN）的遗传风险分类是基于接受强化化疗的年轻成年人的数据制定的。来自接受非强化治疗患者的新分析促使提出了一个专门针对这一患者群体的 ELN 遗传风险分类建议。

相似文献

1
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.成人 AML 患者接受强度较低治疗的遗传风险分类：2024 年 ELN 建议。
Blood. 2024 Nov 21;144(21):2169-2173. doi: 10.1182/blood.2024025409.
2
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.2022年欧洲白血病网风险分层系统对接受强化化疗的18至65岁初诊急性髓系白血病患者预后意义的验证
Am J Hematol. 2023 May;98(5):760-769. doi: 10.1002/ajh.26892. Epub 2023 Mar 13.
3
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.验证 2017 年欧洲白血病网络分类与 NPM1 和 FLT3 内部串联重复基因型的急性髓系白血病。
Cancer. 2019 Apr 1;125(7):1091-1100. doi: 10.1002/cncr.31885. Epub 2018 Dec 6.
4
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.TET2 突变改善了急性髓系白血病的新欧洲白血病网络风险分类：癌症和白血病组 B 研究。
J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742. Epub 2011 Feb 22.
5
ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.ELN 2017 分类显著影响接受强化诱导化疗的急性髓细胞白血病患者的早期死亡风险。
Ann Hematol. 2022 Feb;101(2):309-316. doi: 10.1007/s00277-021-04716-4. Epub 2022 Jan 6.
6
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.验证和完善 2017 年修订的欧洲白血病网络急性髓系白血病遗传风险分层。
Leukemia. 2020 Dec;34(12):3161-3172. doi: 10.1038/s41375-020-0806-0. Epub 2020 Mar 30.
7
Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.评估 2022 年欧洲白血病网络风险分类系统在中国真实世界队列中的表现。
Cancer Med. 2023 Dec;12(24):21615-21626. doi: 10.1002/cam4.6696. Epub 2023 Dec 14.
8
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.欧洲白血病网络标准化系统报告成人急性髓细胞白血病细胞遗传学和分子改变的预后意义。
J Clin Oncol. 2012 Dec 20;30(36):4515-23. doi: 10.1200/JCO.2012.43.4738. Epub 2012 Sep 17.
9
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.验证 2022 年欧洲白血病网络急性髓细胞白血病风险分层。
Sci Rep. 2024 Apr 12;14(1):8517. doi: 10.1038/s41598-024-57295-5.
10
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.

引用本文的文献

1
Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand.阿扎胞苷联合维奈克拉治疗急性髓系白血病的真实世界疗效：一项来自泰国的多中心回顾性队列研究
Ther Adv Hematol. 2025 Sep 9;16:20406207251372770. doi: 10.1177/20406207251372770. eCollection 2025.
2
Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.60至75岁、预后良好、NPM1突变的急性髓系白血病患者接受强化化疗与维奈托克/去甲基化药物治疗的对比
Blood Neoplasia. 2025 Jun 30;2(4):100133. doi: 10.1016/j.bneo.2025.100133. eCollection 2025 Nov.
3
Does Time Matter From Diagnosis to Induction in Acute Myeloid Leukemia?
急性髓系白血病从诊断到诱导治疗的时间重要吗？
J Hematol. 2025 Jul 8;14(4):202-209. doi: 10.14740/jh2075. eCollection 2025 Aug.
4
Upregulation of EMP3 in acute myeloid leukemia: a study based on data mining, RT-qPCR and immunohistochemistry.急性髓系白血病中EMP3的上调：一项基于数据挖掘、RT-qPCR和免疫组织化学的研究
Discov Oncol. 2025 Sep 2;16(1):1668. doi: 10.1007/s12672-025-03368-4.
5
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.靶向凋亡的BH3模拟物：改变急性髓系白血病患者的治疗方式
Nat Rev Clin Oncol. 2025 Sep 1. doi: 10.1038/s41571-025-01068-0.
6
A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia.急性髓系白血病中核磷蛋白（NPM1）的综合基因组分析
Cancers (Basel). 2025 Aug 20;17(16):2710. doi: 10.3390/cancers17162710.
7
Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.AML60+评分对接受去甲基化药物治疗的老年急性髓系白血病患者的预后影响：一项回顾性多中心分析
Cancers (Basel). 2025 Aug 14;17(16):2658. doi: 10.3390/cancers17162658.
8
The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune response.急性髓系白血病常见基因突变与免疫格局之间的相互作用：免疫反应的机制及意义
Front Immunol. 2025 Aug 11;16:1635111. doi: 10.3389/fimmu.2025.1635111. eCollection 2025.
9
Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML.在一组接受VEN/HMA治疗的老年急性髓系白血病患者中，Beat AML基因风险分层模型。
Blood Neoplasia. 2025 Jun 3;2(3):100125. doi: 10.1016/j.bneo.2025.100125. eCollection 2025 Aug.
10
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.不适合接受治疗的新诊断急性髓系白血病患者：2026年治疗算法
Blood Cancer J. 2025 Aug 16;15(1):139. doi: 10.1038/s41408-025-01346-1.